Thanks for the reference to the Entereg trials. Your recollection is correct. One of the 2 PIII trials met its endpoints but the second failed. Here is a link to the PIII press release.
Safety issues also cropped up in the trials, which has caused Adolor to cease further development in OBD. FWIW, NKTR's CEO Howard Robin, stated that there is strong partnering interest in NKTR-118. GSK paid Adolor a $50 million upfront fee in 2002 to partner Entereg for OBD and the other indications.
Market Data 
Markets 
AI
